Please assess the completion status of the following clinical trial:

Trial Title: Trial of Decitabine in Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have diagnosed acute myeloid leukemia.~2. Must have a life expectancy of at least 12 weeks.~3. Must sign informed consent.~Exclusion Criteria:~1. Must not have acute promyelocytic leukemia (M3 classification)~2. Must not have any other active systemic malignancies.~3. Must not have inaspirable bone marrow.~4. Must not have received previous chemotherapy (except hydroxyurea) for any myeloid disorder.~5. Must not have chronic respiratory disease that requires continuous oxygen use.~6. Must not have received any experimental drug within 4 weeks before randomization.~7. Must not be a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization.~8. Must not have known HIV.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).